Colorectal cancer (CRC) ranks among the prevalent gastrointestinal cancers globally ... And the relationship of HDCA mediating the Epiregulin (EREG)/Epidermal Growth Factor Receptor (EGFR) signaling ...

For locally advanced and advanced NSCLC, epidermal growth factor receptor (EGFR ... cancer or cholangiocarcinoma. However, the expression of α2,3-sialylate type 1 (SLeA) is primarily detected for ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback. Zipalertinib appeared safe and ...

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...

There's no doubt lung cancer has a genetic component ... by making them more aggressive. Some EGFR mutations are inherited; others are acquired. When these genes are altered, they tend to become ...

Several mechanisms of resistance to erlotinib and gefitinib have been described in laboratory-based models (Figure 3).

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

1Department of Cancer Biology and Genetics, James Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio. 3Pelotonia Institute for Immuno-Oncology, James ...

Incorporating genomic testing into the management of cervical cancer allows for the creation of personalized treatment plans ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...